# Rewind Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rewind-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Leuven, Belgium
- Website: www.rewindtherapeutics.com
- Total disclosed funding: $18M
- Latest round: Series A (Dec 22, 2017)
- Investors on record: 4

## About

Rewind Therapeutics focuses on developing innovative therapeutic solutions to address unmet medical needs, particularly in oncology and neurodegenerative diseases, enhancing treatment efficacy through advanced biotherapeutics.Rewind Therapeutics is engaged in the development of advanced biotherapeutics targeting specific disease mechanisms. Founded in Leuven, Belgium, the company has evolved strategically without major pivots. The latest funding round, Series A, raised EUR 15.20 mn from investors including Boehringer Ingelheim Venture, K.U. Leuven Research & Development, and others. The company's founder has a history of involvement in biotechnology ventures but specific details on previous companies are not disclosed. Rewind Therapeutics has secured a total of EUR 15.20 mn raised to date, with its latest deal occurring on January 25, 2023.Rewind Therapeutics specializes in the development of innovative therapeutic solutions aimed at addressing unmet medical needs within the healthcare landscape. The company's core product offerings focus on advanced biotherapeutics designed to target specific disease mechanisms, thereby improving patient outcomes. Their flagship products are formulated to enhance treatment efficacy for conditions where traditional therapies have proven inadequate. Aimed at healthcare providers and institutions, these products cater to both acute and chronic conditions, with particular emphasis on applications in oncology and neurodegenerative diseases. Rewind Therapeutics markets its products primarily in North America and Europe, strategically targeting regions with a high demand for novel therapeutic interventions.The revenue model of Rewind Therapeutics is structured around both direct-to-consumer and business-to-business transactions, reflecting a diverse client base that includes healthcare providers, hospitals, and research institutions. The company engages in partnerships with healthcare systems and pharmaceutical distributors to facilitate the delivery of its products, establishing a robust channel for revenue generation. Transactions typically involve bulk purchasing agreements for their therapeutic products, which may include subscription-based services for ongoing support and education on product usage. Pricing structures are aligned with industry standards, focusing on value-driven solutions that meet the needs of their clients while ensuring accessibility for end-users. Notably, Rewind Therapeutics emphasizes the long-term benefits of its therapies, fostering sustained relationships with healthcare professionals who advocate for their innovative solutions.Rewind Therapeutics plans to utilize recent funding from its Series A round to advance its lead program into clinical development and expand its drug pipeline. The company is focused on launching new therapeutic products in the coming years, targeting the oncology and neurodegenerative treatment markets. Expansion efforts include increasing market presence in North America and Europe, with specific initiatives aimed for 2024. The funding will support these initiatives by facilitating the necessary clinical trials and research to enhance their product offerings.

## Funding rounds

- Series A, Dec 22, 2017, $18M — K.U. Leuven Research & Development, M Ventures, PMV, Boehringer Ingelheim Venture

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A